• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Re: Nicholas J. Giacalone, William U. Shipley, Rebecca H. Clayman, et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Eur Urol 2017;71:952-60: Methodological Issues to Avoid Misinterpretation.

作者信息

Safiri Saeid, Ayubi Erfan

机构信息

Managerial Epidemiology Research Center, Department of Public Health, School of Nursing and Midwifery, Maragheh University of Medical Sciences, Maragheh, Iran.

Department of Epidemiology, School of Public Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Department of Epidemiology & Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.

出版信息

Eur Urol. 2017 Sep;72(3):e63. doi: 10.1016/j.eururo.2017.06.008. Epub 2017 Jun 23.

DOI:10.1016/j.eururo.2017.06.008
PMID:28648368
Abstract
摘要

相似文献

1
Re: Nicholas J. Giacalone, William U. Shipley, Rebecca H. Clayman, et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Eur Urol 2017;71:952-60: Methodological Issues to Avoid Misinterpretation.回复：尼古拉斯·J·贾卡洛内、威廉·U·希普利、丽贝卡·H·克莱曼等。肌肉浸润性膀胱癌患者膀胱保留三联疗法的长期疗效：麻省总医院经验的最新分析。《欧洲泌尿外科杂志》2017年；71:952 - 60：避免误解的方法学问题。
Eur Urol. 2017 Sep;72(3):e63. doi: 10.1016/j.eururo.2017.06.008. Epub 2017 Jun 23.
2
Reply to Saeid Safiri and Erfan Ayubi's Letter to the Editor re: Nicholas J. Giacalone, William U. Shipley, Rebecca H. Clayman, et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Eur Urol 2017;71:952-60. Methodological Issues to Avoid Misinterpretation.对赛义德·萨菲里和埃尔凡·阿尤比致编辑信的回复：关于尼古拉斯·J·贾卡洛内、威廉·U·希普利、丽贝卡·H·克莱曼等人的《肌肉浸润性膀胱癌患者保膀胱三联疗法的长期疗效：麻省总医院经验的最新分析》。《欧洲泌尿外科杂志》2017年；71卷：952 - 60页。避免误解的方法学问题。
Eur Urol. 2017 Sep;72(3):e64-e65. doi: 10.1016/j.eururo.2017.06.007. Epub 2017 Jun 19.
3
Re: Jason A. Efstathiou, Daphna Y. Spiegel, William U. Shipley, et al. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol 2012;61:705-11.回复：杰森·A·埃夫斯塔西乌、达芙娜·Y·施皮格尔、威廉·U·希普利等。侵袭性膀胱癌综合治疗选择性膀胱保留的长期疗效：麻省总医院的经验。《欧洲泌尿外科杂志》2012年；61卷：705 - 11页
Eur Urol. 2012 Aug;62(2):e41; author reply e42. doi: 10.1016/j.eururo.2012.04.054. Epub 2012 May 8.
4
Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.保留膀胱的三联疗法治疗肌层浸润性膀胱癌患者的长期疗效：马萨诸塞州综合医院经验的更新分析。
Eur Urol. 2017 Jun;71(6):952-960. doi: 10.1016/j.eururo.2016.12.020. Epub 2017 Jan 9.
5
Re: Phillip J. Gray, Stacey A. Fedewa, William U. Shipley, et al. Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base. Eur Urol 2013;63:823-9.回复：菲利普·J·格雷、斯泰西·A·费德瓦、威廉·U·希普利等人。美国肌肉浸润性膀胱癌的潜在治愈性疗法应用：来自国家癌症数据库的结果。《欧洲泌尿外科杂志》2013年；63卷：823 - 829页。
Eur Urol. 2013 Oct;64(4):e84-5. doi: 10.1016/j.eururo.2013.06.039. Epub 2013 Jul 2.
6
Re: J. Alfred Witjes, Thierry Lebret, Eva M. Compérat, et al. Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. Eur Urol 2017;71:462-75.回复：J. 阿尔弗雷德·维特耶斯、蒂埃里·勒布雷、伊娃·M. 孔佩拉特等。《2016年欧洲泌尿外科学会肌肉浸润性和转移性膀胱癌指南更新》。《欧洲泌尿外科杂志》2017年；71卷：462 - 475页。
Eur Urol. 2017 Aug;72(2):e45. doi: 10.1016/j.eururo.2017.02.031. Epub 2017 Mar 6.
7
Re: Ben J. Challacombe, Bernard H. Bochner, Prokar Dasgupta, et al. The role of laparoscopic and robotic cystectomy in the management of muscle-invasive bladder cancer with special emphasis on cancer control and complications. Eur Urol 2011;60:767-75.
Eur Urol. 2012 Apr;61(4):e29; author reply e30. doi: 10.1016/j.eururo.2011.12.015. Epub 2011 Dec 21.
8
Reply from Authors re: Girish S. Kulkarni, Zachary Klaassen. Trimodal Therapy is Inferior to Radical Cystectomy for Muscle-invasive Bladder Cancer using Population-level Data: Is There Evidence in the (Lack of) Details? Eur Urol 2017;72:488-9: Using the National Cancer Data Base to Compare Treatment Modalities for Localized Muscle-invasive Bladder Cancer.作者回复：关于Girish S. Kulkarni、Zachary Klaassen。利用人群水平数据，三联疗法治疗肌层浸润性膀胱癌劣于根治性膀胱切除术：（缺乏）细节中有证据吗？《欧洲泌尿外科杂志》2017年；72卷：488 - 489页：利用国家癌症数据库比较局限性肌层浸润性膀胱癌的治疗方式
Eur Urol. 2017 Oct;72(4):489-491. doi: 10.1016/j.eururo.2017.05.021. Epub 2017 May 30.
9
Rebuttal from author re: Axel Heidenreich. Muscle-invasive urothelial carcinoma of the bladder: neoadjuvant chemotherapy enables organ preserving therapy in carefully selected patients. Eur Urol 2008;54:21-23.作者对Axel Heidenreich的反驳：膀胱肌层浸润性尿路上皮癌：新辅助化疗使精心挑选的患者能够接受保留器官治疗。《欧洲泌尿外科杂志》2008年；54卷：21 - 23页
Eur Urol. 2008 Jul;54(1):23-4. doi: 10.1016/j.eururo.2008.01.053. Epub 2008 Jan 28.
10
Re: Richard J. Sylvester, Willem Oosterlinck. An immediate instillation after transurethral resection of bladder tumor in non-muscle-invasive bladder cancer: has the evidence changed? Eur Urol 2009;56;43-5.回复：理查德·J·西尔维斯特、威廉·奥斯特林克。非肌层浸润性膀胱癌经尿道膀胱肿瘤切除术后即刻灌注：证据有变化吗？《欧洲泌尿外科杂志》2009年；56卷；43 - 5页
Eur Urol. 2010 Mar;57(3):e28-9; author reply e30. doi: 10.1016/j.eururo.2009.11.026. Epub 2009 Nov 17.